US biotechnology major Genzyme's profit for 2008 fell 12% year-on-year, due to rocketing expenses, particularly relating to R&D costs.
R&D expenses rose 78% to $1.31 billion. Net income fell to $421.1 million, or $1.57 per share, versus $480.2 million, or $1.82 per share. Revenue, however, increased 21% to $4.6 billion.
Revenue driven by genetic disease division
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze